The embedded finance company, which posted a loss last year, hired Citigroup to explore its strategic options and named an ...

Equities research analysts at William Blair lowered their Q2 2026 earnings per share estimates for Zumiez in a report ...

Investment analysts at William Blair cut their Q1 2025 earnings per share (EPS) estimates for U.S. Physical Therapy in a ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...

Fintel reports that on March 12, 2025, William Blair downgraded their outlook for Udemy (NasdaqGS:UDMY) from Outperform to ...

Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...

We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Funding characterized by the federal government as a new investment into a network of northern military hubs is, in fact, not ...

William Blair upgraded Zealand Pharma (ZLDPF) to Outperform from Market Perform without a price target The firm sees the recent share pullback ...

BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.